Pfizer raises 2026 forecasts as Eliquis, cancer drugs drive Q3 beat - Reuters

More in Business

• Nexperia sues Wingtech and its founder, demanding compensation for damages

  The legal battle reflects escalating internal conflict between the Dutch semiconductor manufacturer and its controlling Chinese shareholder. Accusing leadership of detrimental conduct, the firm is seeking formal financial restitution for harm inflicted on its ongoing commercial operations. The dispute now moves to European jurisdiction for judicial resolution.

  1 min read
• V-Mart Retail Q2 loss widens to Rs 16 crore

  Rising operational expenditures outpaced top-line expansion for the value fashion chain, causing its quarterly deficit to nearly double compared to the previous year. Although consumer demand drove steady growth across retail operations and digital platforms, higher overall spending pressured profitability. Investors absorbed the earnings update neutrally, leaving company shares virtually unchanged at the market close.

  1 min read
• Minda Corp Q2 Results: Net profit jumps 68% to Rs 143 crore on strong revenue growth

  Strong demand across key automotive segments and an increasing focus on electrification bolstered quarterly operational performance for the auto components manufacturer. This commercial momentum helped offset a substantial increase in raw material costs that drove overall expenditure upward. Looking forward, ongoing investments in domestic production, technology, and vehicle electronics aim to capture additional market value per unit.

  1 min read